Literature DB >> 15836924

JIP1 regulates neuronal apoptosis in response to stress.

Zhaohui Dong1, Li Zhou, Keith Del Villar, Mahin Ghanevati, Vartan Tashjian, Carol A Miller.   

Abstract

We examined if the relative expression of JNK-interacting protein 1 (JIP1) and phosphorylated c-Jun N-terminal kinase (JNK) regulates cell signaling and contributes to selective neuronal vulnerability in response to environmental stress. In clonal neuroblastoma cultures, stresses such as hypoxia, ischemia, Abeta peptides, and UV irradiation rapidly reduced JIP1 expression. JIP1 mRNA expression was also down-regulated by UV stress and was accompanied by increased JNK and c-Jun activation and cell death. JIP1 protein reduction was partially reversed both by inhibitors predominantly of caspase 3 and of the JNK pathway and resulted in significantly increased cell survival. Conversely, overexpression of JIP1 decreased both nuclear translocation of activated-JNK, and c-Jun phosphorylation induced by either UV irradiation, or the JNK upstream activators, MKK7 or MEKK1. Cell death was reduced about 50% compared to GFP-transfected controls. JIP1 overexpression did not facilitate either JNK expression or activation. In the normal, non-stressed human hippocampus and rat hippocampal organotypic cultures, JIP1 and JNK3 were inversely expressed with more JIP1 in CA2 and CA3 and less in CA1 neurons. In the human hippocampus, transient hypoxia/ischemia selectively spares neurons in CA2 and CA3 and induces death of neurons in the hippocampal CA1 subregion. In the cultures, ischemia reduced JIP1 expression and activated JNK, c-Jun, and caspase 3. Inhibitors of the JNK pathway, JNK activation directly and of caspase 3 activation each partially reversed these effects. Thus, under certain stress conditions, down-regulation of JIP1 expression makes neurons more susceptible to apoptosis, suggesting JIP may serve as an anti-apoptosis factor.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15836924     DOI: 10.1016/j.molbrainres.2004.10.039

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN: 0169-328X


  11 in total

Review 1.  Genetic and Molecular Biology of Multiple Sclerosis Among Iranian Patients: An Overview.

Authors:  Meysam Moghbeli
Journal:  Cell Mol Neurobiol       Date:  2019-09-03       Impact factor: 5.046

2.  Sh3rf2/POSHER protein promotes cell survival by ring-mediated proteasomal degradation of the c-Jun N-terminal kinase scaffold POSH (Plenty of SH3s) protein.

Authors:  Michael Wilhelm; Nickolay V Kukekov; Travis L Schmit; Katherine V Biagas; Andrew A Sproul; Stephen Gire; Margaret E Maes; Zhiheng Xu; Lloyd A Greene
Journal:  J Biol Chem       Date:  2011-11-28       Impact factor: 5.157

3.  Screening of AMP-activated protein kinase alpha2 subunit interacting proteins by bacterial two-hybrid system.

Authors:  Qing-Ying Fu; Yu-Qi Gao
Journal:  Mol Biol Rep       Date:  2007-11-22       Impact factor: 2.316

4.  Vaccinia-related kinase 2 modulates the stress response to hypoxia mediated by TAK1.

Authors:  Sandra Blanco; Claudio Santos; Pedro A Lazo
Journal:  Mol Cell Biol       Date:  2007-08-20       Impact factor: 4.272

5.  Common variants at VRK2 and TCF4 conferring risk of schizophrenia.

Authors:  Stacy Steinberg; Simone de Jong; Ole A Andreassen; Thomas Werge; Anders D Børglum; Ole Mors; Preben B Mortensen; Omar Gustafsson; Javier Costas; Olli P H Pietiläinen; Ditte Demontis; Sergi Papiol; Johanna Huttenlocher; Manuel Mattheisen; René Breuer; Evangelos Vassos; Ina Giegling; Gillian Fraser; Nicholas Walker; Annamari Tuulio-Henriksson; Jaana Suvisaari; Jouko Lönnqvist; Tiina Paunio; Ingrid Agartz; Ingrid Melle; Srdjan Djurovic; Eric Strengman; Gesche Jürgens; Birte Glenthøj; Lars Terenius; David M Hougaard; Torben Ørntoft; Carsten Wiuf; Michael Didriksen; Mads V Hollegaard; Merete Nordentoft; Ruud van Winkel; Gunter Kenis; Lilia Abramova; Vasily Kaleda; Manuel Arrojo; Julio Sanjuán; Celso Arango; Swetlana Sperling; Moritz Rossner; Michele Ribolsi; Valentina Magni; Alberto Siracusano; Claus Christiansen; Lambertus A Kiemeney; Jan Veldink; Leonard van den Berg; Andres Ingason; Pierandrea Muglia; Robin Murray; Markus M Nöthen; Engilbert Sigurdsson; Hannes Petursson; Unnur Thorsteinsdottir; Augustine Kong; I Alex Rubino; Marc De Hert; János M Réthelyi; István Bitter; Erik G Jönsson; Vera Golimbet; Angel Carracedo; Hannelore Ehrenreich; Nick Craddock; Michael J Owen; Michael C O'Donovan; Mirella Ruggeri; Sarah Tosato; Leena Peltonen; Roel A Ophoff; David A Collier; David St Clair; Marcella Rietschel; Sven Cichon; Hreinn Stefansson; Dan Rujescu; Kari Stefansson
Journal:  Hum Mol Genet       Date:  2011-07-26       Impact factor: 6.150

6.  Disassembly of the JIP1/JNK molecular scaffold by caspase-3-mediated cleavage of JIP1 during apoptosis.

Authors:  Mahesh Vaishnav; Marion MacFarlane; Martin Dickens
Journal:  Exp Cell Res       Date:  2011-01-13       Impact factor: 3.905

7.  Anti-inflammatory Effect of Glucagon Like Peptide-1 Receptor Agonist, Exendin-4, through Modulation of IB1/JIP1 Expression and JNK Signaling in Stroke.

Authors:  Soojin Kim; Jaewon Jeong; Hye-Seon Jung; Bokyung Kim; Ye-Eun Kim; Da-Sol Lim; So-Dam Kim; Yun Seon Song
Journal:  Exp Neurobiol       Date:  2017-08-31       Impact factor: 3.261

8.  Modulation of interleukin-1 transcriptional response by the interaction between VRK2 and the JIP1 scaffold protein.

Authors:  Sandra Blanco; Marta Sanz-García; Claudio R Santos; Pedro A Lazo
Journal:  PLoS One       Date:  2008-02-20       Impact factor: 3.240

9.  Effects of VRK2 (rs2312147) on white matter connectivity in patients with schizophrenia.

Authors:  Hoyoung Sohn; Borah Kim; Keun Hyang Kim; Min-Kyoung Kim; Tai Kiu Choi; Sang-Hyuk Lee
Journal:  PLoS One       Date:  2014-07-31       Impact factor: 3.240

Review 10.  JNK3 as Therapeutic Target and Biomarker in Neurodegenerative and Neurodevelopmental Brain Diseases.

Authors:  Clara Alice Musi; Graziella Agrò; Francesco Santarella; Erika Iervasi; Tiziana Borsello
Journal:  Cells       Date:  2020-09-28       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.